Menu +

Tag: medicines

Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality

• 2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% – bringing potential reach to over 23 million patients across these initiatives • Enhanced target for full carbon neutrality across all company operations and entire supply chain by 20301 • New collaboration with […]

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers

• Roche will obtain co-development and co-commercialisation rights for pralsetinib, an investigational, precision therapy in late-stage development for people with RET-altered non-small cell lung cancer, various types of thyroid cancer and other solid tumours. • Blueprint Medicines and Roche will collaborate on the development of pralsetinib. • Roche and Blueprint Medicines will co-commercialise pralsetinib in […]

Coronavirus: €117 million granted for treatments and diagnostics through the Innovative Medicines Initiative

The Commission announced today that 8 large-scale research projects, aimed at developing treatments and diagnostics for the coronavirus,were selected in a fast-track call for proposals, launched in March by the Innovative Medicines Initiative (IMI), a public-private partnership. In order to fund a larger number of high-quality proposals, the Commission increased its commitment to €72 million […]

Covid-19 : Guidance on more regulatory flexibility for medicines

The European Commission, EMA and the European medicines regulatory network have developed a Q&A document to provide guidance to stakeholders on adaptations to the regulatory framework to address challenges arising from the COVID-19 pandemic, with a particular focus on crucial medicines for use in COVID-19 patients. The document explains some regulatory flexibilities that can be […]

EU Guidelines to ensure supply and availability of medicines

Coronavirus: Statement by Ursula von der Leyen, President of the European Commission, on guidelines to ensure supply and availability of medicines here On 8 April 2020, Ursula von der Leyen, President of the European Commission, recorded a video message at the European Commission in Brussels, Belgium, on guidelines to ensure supply and availability of medicines.These guidelines […]